

Case Number:	CM14-0016121		
Date Assigned:	08/27/2014	Date of Injury:	03/13/2006
Decision Date:	09/25/2014	UR Denial Date:	02/01/2014
Priority:	Standard	Application Received:	02/07/2014

HOW THE IMR FINAL DETERMINATION WAS MADE

MAXIMUS Federal Services sent the complete case file to an expert reviewer. He/she has no affiliation with the employer, employee, providers or the claims administrator. The expert reviewer is Board Certified in Family Medicine and is licensed to practice in California. He/she has been in active clinical practice for more than five years and is currently working at least 24 hours a week in active practice. The expert reviewer was selected based on his/her clinical experience, education, background, and expertise in the same or similar specialties that evaluate and/or treat the medical condition and disputed items/services. He/she is familiar with governing laws and regulations, including the strength of evidence hierarchy that applies to Independent Medical Review determinations.

CLINICAL CASE SUMMARY

The expert reviewer developed the following clinical case summary based on a review of the case file, including all medical records:

This is a 51-year-old who reported an industrial injury to the neck on March 13, 2006, over eight (8) years ago attributed to the performance of her customary job tasks. The the patient complained of persistent bilateral neck pain. The patient was noted to be taking Voltare in 1% topical gel; Ultram 50 mg; Lidoderm patches; and Motrin PRN. The objective findings on examination included diminished range of motion to the cervical spine and right shoulder; nerve root tension signs were negative bilaterally; Tinel's sign positive bilaterally; Phalen's sign negative bilaterally; muscle strength 5/5. The diagnoses included s/p right shoulder surgery; SLAP lesion of the right shoulder; focal partial tear of the right supraspinatus tendon; right shoulder rotator cuff tendinitis with impingement; moderate right AC joint degenerative changes; right elbow medial epicondylitis; right wrist de Quervain's tendinitis; right carpal tunnel syndrome; repetitive upper extremity injuries; right C6 cervical radiculopathy; central disc protrusion at C5-C6; central disc protrusion at C6-C7; cervical spinal stenosis; and cervical sprain/strain. The treatment plan included eight sessions of physical therapy directed to the cervical spine and shoulders and hands; a prescription for Lidoderm patches with five refills; and a tens unit trial.

IMR ISSUES, DECISIONS AND RATIONALES

The Final Determination was based on decisions for the disputed items/services set forth below:

Lidoderm patches (quantity unknown) with five refills: Upheld

Claims Administrator guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Topical Lidocaine.

MAXIMUS guideline: Decision based on MTUS ACOEM Chapter 3 Initial Approaches to Treatment Page(s): 47-48, Chronic Pain Treatment Guidelines ANTI-INFLAMMATORY MEDICATIONS; CHRONIC PAIN CHAPTER'S TOPICAL ANALGESICS Page(s): 67-68; 111-113. Decision based on Non-MTUS Citation Official Disability Guidelines (ODG) pain chapter medications for chronic pain; topical analgesics.

Decision rationale: The Initial Approaches to Treatment Chapter of the American College of Occupational and Environmental Medicine (ACOEM) Practice Guidelines does not recommend the use of Lidoderm patches for pain control as the patches or ointment are only FDA approved for the treatment of neuropathic pain attributed to post herpetic neuralgia. The patient is being treated with Lidoderm patches for chronic shoulder and back pain. There is no medical necessity for the use of the Lidoderm patches for the objective findings documented on examination. The request for authorization of the Lidoderm patches is not supported with objective evidence and is not recommended as a first line treatment for the treatment of chronic neck/shoulder pain. There is no objective evidence that the Lidoderm patches are more effective than the many available alternatives for the treatment of chronic pain. There is no objective evidence to support the use of Lidoderm patches for the stated symptoms, as there are available alternatives. There is no objective evidence to support the use of topical lidocaine for the treatment of the documented diagnoses. The applicable evidence-based guidelines state that more research is required prior to endorsing the use of Lidoderm patches for the treatment of chronic pain. The prescription of Lidoderm patches is FDA approved only for post herpetic neuralgia and is not to be used as a first line treatment. The provider provides no rationale for the use of the dispensed/prescribed Lidoderm patches over the readily available medical alternatives. The prescription of the Lidoderm patches is inconsistent with evidence-based guidelines. There are no prescribed antidepressants or gabapentin to support the medical necessity of Lidoderm topical patches. Evidence-based guidelines necessitate documentation of localized peripheral pain after there has been evidence of a trial of first-line therapy (tri-cyclic or SNRI [serotonin-norepinephrine reuptake inhibitor] anti-depressants or an AED [anti-epileptic drug], such as, gabapentin or Lyrica) to support the medical necessity of Lidoderm patch. The patient is not taking Neurontin, thus Lidoderm is not appropriate for the treatment of this patient. There is no objective evidence to support the use of Lidoderm patches for the continuous and daily treatment of chronic shoulder or back pain. There is no current clinical documentation that indicates that the patient has a localized area of neuropathic pain, which this medication would be medically necessary. There is no demonstrated medical necessity for Lidoderm patches or topical lidocaine ointment to treat the effects of the industrial injury. The ODG identifies that Lidoderm is the brand name for a lidocaine patch produced by Endo Pharmaceuticals. Topical lidocaine may be recommended for localized peripheral pain after there has been evidence of a trial of first-line therapy (tri-cyclic or SNRI anti-depressants or an AED such as gabapentin or Lyrica). This is not a first-line treatment and is only FDA approved for post-herpetic neuralgia. Further research is needed to recommend this treatment for chronic neuropathic pain disorders other than post-herpetic neuralgia. Formulations that do not involve a dermal-patch system are generally indicated as local anesthetics and anti-pruritics. Additionally, ODG states that topical lidocaine 5% patch/ointment has been approved by the FDA for post-herpetic neuralgia, and is used off-

label for diabetic neuropathy and other neuropathic pain. It has been shown to be useful in treating various chronic neuropathic pain conditions in open-label trials. (Argoff, 2006) (ODG, Pain Chapter). Therefore, the request for Lidoderm patches (quantity unknown) with five refills is not medically necessary or appropriate.